| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 08/12/2004 | US20040156838 inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination; inducing a combined antibody and CTK response specific for IgE |
| 08/12/2004 | US20040156825 Short immunomodulatory oligonucleotides |
| 08/12/2004 | US20040156816 Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| 08/12/2004 | CA2514551A1 Slowly digestible starch |
| 08/12/2004 | CA2514396A1 Compositions and methods containing substituted quinolines and substituted diphenylsulfones |
| 08/12/2004 | CA2514327A1 Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
| 08/12/2004 | CA2514252A1 A therapeutic composition for the treatment of hiv-1 and hiv-2 |
| 08/12/2004 | CA2514125A1 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | CA2514117A1 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | CA2514066A1 Sensitive proteasome sensor constructs and methods for their design and use |
| 08/12/2004 | CA2514062A1 Compositions and methods for treating cancer using igsf9 and liv-1 |
| 08/12/2004 | CA2513975A1 A method of treating breast cancer with androgen receptor antagonists |
| 08/12/2004 | CA2513769A1 Method for evaluating the efficacy of certain cancer treatments |
| 08/12/2004 | CA2513598A1 Use of the cathelicidin ll-37 and derivatives thereof for wound healing |
| 08/12/2004 | CA2512879A1 N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| 08/12/2004 | CA2512174A1 Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof |
| 08/12/2004 | CA2512169A1 Polymerized hemoglobin solutions having reduced amount of tetramer and method for preparing |
| 08/12/2004 | CA2493899A1 Controlled release modifying complex and pharmaceutical compositions thereof |
| 08/12/2004 | CA2485568A1 Variant integrin polypeptides and uses thereof |
| 08/11/2004 | EP1444987A2 Oral vaccine against diarrhea |
| 08/11/2004 | EP1443945A1 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
| 08/11/2004 | EP1443932A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 08/11/2004 | EP1286681B1 Irradiation of ispaghula |
| 08/11/2004 | EP1135381B1 Eletriptan hydrobromide monohydrate |
| 08/11/2004 | EP0821728B1 Tie-2 ligands, methods of making and uses thereof |
| 08/11/2004 | CN1520403A Novel polymorph v of torasemide |
| 08/11/2004 | CN1520307A Combination of Chinese traditional medicine for treating angina pectoris as well as preparation method and usage |
| 08/11/2004 | CN1520285A Tablet comprising cetirizine and pseudoephedrine |
| 08/11/2004 | CN1161351C Novel form of S-omeprazole |
| 08/11/2004 | CN1161331C Hydrazine derivatives |
| 08/11/2004 | CN1161120C Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylasis treatment of obesity |
| 08/11/2004 | CN1161114C Usage of compound in pharmaceutic mfg. for treating sleep apnoea |
| 08/10/2004 | US6774122 Sustained release; injection of fulvestrant |
| 08/10/2004 | US6774121 Phospholipid prodrugs of anti-proliferative drugs |
| 08/10/2004 | US6773714 Polymeric delivery formulations of leuprolide with improved efficacy |
| 08/05/2004 | WO2004064789A2 Quaternary antimuscarinic compounds for the treatment of bladder diseases |
| 08/05/2004 | WO2004064788A2 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 08/05/2004 | WO2004064787A2 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 08/05/2004 | WO2004064786A2 Article for debridement and detoxification of wounds |
| 08/05/2004 | WO2004064785A2 Cancer therapy sensitizer |
| 08/05/2004 | WO2004064784A2 Composition and method for preventing or treating a virus infection |
| 08/05/2004 | WO2004064783A2 Eosinophil-derived neurotoxin as a marker for ovarian cancer |
| 08/05/2004 | WO2004064782A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 08/05/2004 | WO2004064781A2 Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs |
| 08/05/2004 | WO2004064779A2 Use of nitroglycerin to relieve nocturnal muscle cramps |
| 08/05/2004 | WO2004064778A2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/05/2004 | WO2004064777A2 Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer |
| 08/05/2004 | WO2004064776A2 Methods of preparation of live attenuated bacterial vaccines by alteration of dna adenine methylase (dam) activity in those bacteria |
| 08/05/2004 | WO2004064775A2 Sigma-2 receptor agonists and their use in the treatment of hiv infection |
| 08/05/2004 | WO2004064774A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 08/05/2004 | WO2004064773A2 Inhibition of e3-ubiquitin ligase hakai for treatment of proliferative disorders |
| 08/05/2004 | WO2004064772A2 Methods and dosage forms with modified viscosity layers |
| 08/05/2004 | WO2004064771A2 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents |
| 08/05/2004 | WO2004064770A2 Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney |
| 08/05/2004 | WO2004064769A2 Methods for making and using topical delivery agents |
| 08/05/2004 | WO2004064767A2 Nitric oxide inducing agents |
| 08/05/2004 | WO2004064765A2 Herpesvirus amplicon particles |
| 08/05/2004 | WO2004064763A2 Cleavage of serum response factor in cardiac diagnosis and therapy |
| 08/05/2004 | WO2004064762A2 Novel cocrystallization |
| 08/05/2004 | WO2004064761A2 Therapeutically active compounds |
| 08/05/2004 | WO2004064760A2 Aptamer therapeutics useful in ocular pharmacotherapy |
| 08/05/2004 | WO2004064759A2 Use of tryptanthrin compounds for immune potentiation |
| 08/05/2004 | WO2004064757A2 Absorption enhancing agents |
| 08/05/2004 | WO2004064755A2 Methods for inhibiting proteasome |
| 08/05/2004 | WO2004064751A2 Nanoparticle based stabilization of ir fluorescent dyes |
| 08/05/2004 | WO2004064750A2 Improved constructs for expressing lysosomal polypeptides |
| 08/05/2004 | WO2004064748A2 Compositions and methods for treatment of ovarian cancer |
| 08/05/2004 | WO2004064747A2 Treating androgen deficiency in female (adif)-associated conditions with sarms |
| 08/05/2004 | WO2004064745A2 Method of preparation of heterocyclic molecules with pharmaceutical pharmaceutical excipient cosmeceutical agrochemical and industrial uses |
| 08/05/2004 | WO2004064744A2 Methods for site-directed mutagenesis and targeted randomization |
| 08/05/2004 | WO2004064742A2 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms |
| 08/05/2004 | WO2004064741A2 Compounds, compositions, and methods |
| 08/05/2004 | WO2004064740A2 Sperm specific lysozyme-like proteins |
| 08/05/2004 | WO2004064739A2 Substrate detection assay |
| 08/05/2004 | WO2004064737A2 Therapeutics compositions |
| 08/05/2004 | WO2004064736A2 Treatment of benign prostatic hyperplasia using energolytic agents |
| 08/05/2004 | WO2004064735A2 Treatment of benign prostatic hyperplasia |
| 08/05/2004 | WO2004064734A2 Combination therapies for the treatment of cancer |
| 08/05/2004 | WO2004064733A2 The use of c-raf inhibitors for the treatment of neurodegenerative diseases |
| 08/05/2004 | WO2004064732A2 The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| 08/05/2004 | WO2004064730A2 Compounds, compositions and methods |
| 08/05/2004 | WO2004064729A2 Treatments for snoring using injectable neuromuscular stimulators |
| 08/05/2004 | WO2004064727A2 Method of cancer treatment using hdac inhibitors |
| 08/05/2004 | WO2004064725A2 Oral compositions and methods for treatment of adverse effects or radiation |
| 08/05/2004 | WO2004064721A2 A pyrazolopyrimidine compound and a process for preparing the same |
| 08/05/2004 | WO2004064720A2 A process to apply the effectiveness of coconut flower |
| 08/05/2004 | WO2004064719A2 Synergistic compositions and methods for potentiating anti-oxidative activity |
| 08/05/2004 | WO2004064718A2 Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof |
| 08/05/2004 | WO2004064717A2 Cop 1 for treatment of inflammatory bowel diseases |
| 08/05/2004 | WO2004064713A2 The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors |
| 08/05/2004 | WO2004064711A2 Modulation of deubiquitinase family members |
| 08/05/2004 | WO2004064710A2 Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas |
| 08/05/2004 | WO2004064708A2 Solution for nostril wash |
| 08/05/2004 | WO2004064539A2 Fat substitutes |
| 08/05/2004 | WO2004050015A3 Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof |
| 08/05/2004 | WO2004042359A3 Preformulation analysis and optimization |
| 08/05/2004 | WO2004041159A3 Composition and method for enhancing immune response of swine |
| 08/05/2004 | WO2004037183A3 Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| 08/05/2004 | WO2004037169A3 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/05/2004 | WO2004034962A3 Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |